Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) EPS (Basic) (2021 - 2025)

Coeptis Therapeutics Holdings has reported EPS (Basic) over the past 5 years, most recently at -$2.85 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$2.85 for Q4 2025, up 46.79% from a year ago — trailing twelve months through Dec 2025 was -$13.76 (down 147.41% YoY), and the annual figure for FY2025 was -$2.81, up 49.46%.
  • EPS (Basic) for Q4 2025 was -$2.85 at Coeptis Therapeutics Holdings, up from -$4.17 in the prior quarter.
  • Over the last five years, EPS (Basic) for COEPW hit a ceiling of $3.37 in Q4 2021 and a floor of -$15.8 in Q4 2023.
  • Median EPS (Basic) over the past 5 years was -$0.2 (2022), compared with a mean of -$1.58.
  • Biggest five-year swings in EPS (Basic): surged 86.67% in 2022 and later tumbled 8241.58% in 2025.
  • Coeptis Therapeutics Holdings' EPS (Basic) stood at $3.37 in 2021, then tumbled by 106.11% to -$0.21 in 2022, then crashed by 7574.94% to -$15.8 in 2023, then surged by 66.14% to -$5.35 in 2024, then surged by 46.79% to -$2.85 in 2025.
  • The last three reported values for EPS (Basic) were -$2.85 (Q4 2025), -$4.17 (Q3 2025), and -$5.63 (Q2 2025) per Business Quant data.